


IN THE CLAIMS:

Claim 1 (currently amended): A compound of formula (I):



(I)

wherein:

Ring A is imidazo[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl;

R² is attached to a ring carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, phenyl, heterocyclic group, phenylthio or (heterocyclic group)thio; wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, phenyl or heterocyclic group may be optionally substituted on carbon by one or more G; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from Q;

m is 0-5; wherein the values of R² may be the same or different;

R¹ is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₃alkyl, C₂₋₃alkenyl, C₂₋₃alkynyl, C₁₋₃alkoxy, C₁₋₃alkanoyl, *N*-(C₁₋₃alkyl)amino, *N,N*-(C₁₋₂alkyl)₂amino, C₁₋₃alkanoylamino, *N*-(C₁₋₃alkyl)carbamoyl, *N,N*-(C₁₋₂alkyl)₂carbamoyl, C₁₋₃alkylS(O)_a wherein a is 0 to 2, *N*-(C₁₋₃alkyl)sulphamoyl or *N,N*-(C₁₋₃alkyl)₂sulphamoyl; wherein any C₁₋₂alkyl, C₁₋₃alkyl, C₂₋₃alkenyl or C₂₋₃alkynyl may be optionally substituted on carbon by one or more J;

n is 0 to 2, wherein the values of R¹ may be the same or different;

Ring B is phenyl or phenyl fused to a C₅₋₇cycloalkyl ring;

R³ is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₂₋₆alkenyl or C₂₋₆alkynyl;

p is 0-4; wherein the values of **R³** may be the same or different;

R⁴ is a group A-E-; wherein

A is selected from C₁₋₆alkyl, phenyl, a heterocyclic group, C₃₋₈cycloalkyl, phenylC₁₋₆alkyl, (heterocyclic group)C₁₋₆alkyl or C₃₋₈cycloalkylC₁₋₆cycloalkyl; which C₁₋₆alkyl, phenyl, a heterocyclic group, C₃₋₈cycloalkyl, phenylC₁₋₆alkyl, (heterocyclic group)C₁₋₆alkyl or C₃₋₈cycloalkylC₁₋₆cycloalkyl may be optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R;

E is a direct bond or -O-, -C(O)-, -OC(O)-, -C(O)O-, -N(R^a)C(O)-, -C(O)N(R^a)-, -N(R^a)-, -S(O)_r-, -SO₂N(R^a)- or -N(R^a)SO₂-; wherein R^a is hydrogen or C₁₋₆alkyl optionally substituted by one or more D and r is 0-2;

D is independently selected from oxo, halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, C₁₋₆alkoxycarbonylamino, benzyloxycarbonylamino, *N*-(C₁₋₆alkyl)sulphamoyl and *N,N*-(C₁₋₆alkyl)₂sulphamoyl; wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl or phenyl may be optionally substituted on carbon by one or more K;

q is 0-2; wherein the values of **R⁴** maybe the same or different; and wherein **p + q** ≤ 5;

G, J and K are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphanyl, ethylsulphanyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl,

N-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or
N-methyl-*N*-ethylsulphamoyl; and

Q and R are independently selected from C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkylsulphonyl,
C₁₋₄alkoxycarbonyl, carbamoyl, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)carbamoyl,
benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available
carboxy or hydroxy group thereof.

Claim 2 (**currently amended**): A compound of formula (I) according to claim 1 wherein
R¹ is bromo or 2-hydroxyethylthio and n is 0-1;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable formed from an available
carboxy or hydroxy group ester thereof.

Claim 3 (**currently amended**): A compound of formula (I) according to claim 1 wherein
Ring A is imidazo[1,2a]pyrid-3-yl;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available
carboxy or hydroxy group thereof.

Claim 4 (**currently amended**): A compound of formula (I) according to claim 1 wherein
R² is attached to a ring carbon and is selected from fluoro, chloro, bromo, cyano, methyl,
methoxy, ethylthio, 2-hydroxyethylthio or 2-dimethylaminoethylthio and m is 0-2; wherein the
values of R² may be the same or different;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available
carboxy or hydroxy group thereof.

Claim 5 (**currently amended**): A compound of formula (I) according to claim 1 wherein
R³ is fluoro, chloro, bromo or sulphamoyl; and p is 1;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available
carboxy or hydroxy group thereof.

Claim 6 (currently amended): A compound of formula (I) according to claim 1 wherein R^4 is methyl, ethyl, methoxy, methylthio, acetyl, benzyloxy, mesyl, *N,N*-diethylaminoethoxy, 3-*N,N*-dimethylamino-2-hydroxypropoxy, phenoxy, *N*-methylcarbamoyl, *N,N*-dimethylcarbamoyl, *N*-(3-imidazol-1-ylpropyl)carbamoyl, *N*-[3-(2-oxo-pyrrolidin-1-yl)propyl]carbamoyl, 3,5-dioxapiperidin-1-ylsulphonyl, *N*-cyclopropylsulphamoyl, *N*-cyclopropylmethylsulphamoyl, anilinosulphonyl, *N*-pyrimidin-2-ylsulphamoyl, *N*-methylsulphamoyl, *N*-propylsulphamoyl, *N*-(2-methoxyethyl)sulphamoyl, *N*-(2-methylaminoethyl)sulphamoyl, *N*-(2-isopropylaminoethyl)sulphamoyl, *N*-(2-dimethylaminoethyl)sulphamoyl, *N*-(2-diethylaminoethyl)sulphamoyl, *N*-[2-(hydroxyethylamino)ethyl]sulphamoyl, *N*-[2-(diethylaminoethyl)ethyl]sulphamoyl, *N*-(pyrrolidin-1-ylethyl)sulphamoyl, *N*-[2-(1-methylpyrrolidin-2-yl)ethyl]sulphamoyl, *N*-(2-piperidin-1-ylethyl)sulphamoyl, *N*-(2-piperazin-1-ylethyl)sulphamoyl, *N*-(2-morpholinoethyl)sulphamoyl, *N*-(2-imidazol-4-ylethyl)sulphamoyl, *N*-(3-hydroxypropyl)sulphamoyl, *N*-(2,3-dihydroxypropyl)sulphamoyl, *N*-(3-methoxypropyl)sulphamoyl, *N*-(3-aminopropyl)sulphamoyl, *N*-(3-methylaminopropyl)sulphamoyl, *N*-(3-dimethylaminopropyl)sulphamoyl, *N*-(3-diethylaminopropyl)sulphamoyl, *N*-(3-isopropylaminopropyl)sulphamoyl, *N*-(3-*t*-butoxycarbonylaminopropyl)sulphamoyl, *N*-(3-benzyloxycarbonylaminopropyl)sulphamoyl, *N*-[3-(2-oxopyrrolidin-1-yl)propyl]sulphamoyl, *N*-(3-morpholinopropyl)sulphamoyl, *N*-[3-(4-methylpiperazin-1-yl)propyl]sulphamoyl, *N*-(3-imidazol-1-ylpropyl)sulphamoyl or *N*-(5-hydroxypentyl)sulphamoyl; and *q* is 1;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 7 (currently amended): A compound of formula (I) according to claim 1 wherein Ring B is phenyl;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.


Claim 8 (currently amended): A compound of formula (I) selected from:

2-(4-Sulphamoylanilino)-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;
 2-[4-(*N*-Methylsulphamoyl)anilino]-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;
 2-{4-[*N*-(2-Methoxyethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;
 2-{4-[*N*-(3-Methoxypropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;
 2-{4-[*N*-(3-Isopropylaminopropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl) pyrimidine;
 2-{4-[*N*-(3-Dimethylaminopropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl) pyrimidine;
 2-{4-[*N*-(2-Dimethylaminoethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;
 2-{4-[*N*-(2-Methylaminoethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine; or
 2-{4-[*N*-(2-Methoxyethyl)sulphamoyl]anilino}-4-[5-(2-hydroxyethylthio)imidazo[1,2a]
 pyrid-3-yl]pyrimidine;


or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claim 9 (currently amended): A process for preparing a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof, which process (wherein R¹, R², R³, R⁴, Ring A, Ring B, m, p, q and n are, unless otherwise specified, as defined in formula (I)) comprises of:

a) reaction of a pyrimidine of formula (II):




wherein L is a displaceable group; with an amine of formula (III):




(III)

b) reacting a pyrimidine of formula (IV):



(IV)

with a compound of the formula (V):




(V)

wherein one of M and Q is a displaceable group X and the other is an metallic reagent Y;


or

c) reacting a compounds of formula (VI):



(VI)

with a compound of formula (VII):



(VII)

wherein R⁵ is C₁₋₆alkyl and R⁶ is hydrogen or R¹;

and thereafter optionally if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group.

Claim 10 (**currently amended**): A pharmaceutical composition which comprises a compound of formula (I) according to any one of claims 1 - 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof formed from an available carboxy or hydroxy group, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 11-12 (**cancelled**).

Claim 13 (**currently amended**): A method for treating cancer ~~producing an anti-cancer effect~~ in a warm blooded animal in need thereof which comprises administering to said animal an effective amount of a compound of the formula (I) as claimed in any one of claims 1 - 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.

Claims 14-17 (**cancelled**).

Claim 18 (**new**): A method for inhibiting CDK2 in a warm blooded animal in need thereof which comprises administering to said animal an inhibiting amount of a compound of the formula (I) as claimed in any one of claims 1 – 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester formed from an available carboxy or hydroxy group thereof.